VIDEOSGZERO World with Ian BremmerQuick TakePUPPET REGIMEIan ExplainsGZERO ReportsAsk IanGlobal Stage
Site Navigation
Search
Human content,
AI powered search.
Latest Stories
Start your day right!
Get latest updates and insights delivered to your inbox.
Ian Bremmer's Quick Take:
Hi, everybody. Ian Bremmer here, back in the office in New York City. And I've got my Christmas scarf going, it feels... It's the time of the holidays, get your trees, decorate, right? I usually have a little tree trimming party, which means everybody else comes and trims the tree with me. Not this year, but nonetheless, soon to be, Merry Christmas to everybody and lots to talk about.
I guess, biggest thing on my mind right now is the rollout of these vaccines. I mean, on the one hand it's I know it's challenging the push and pull of the United States right now being in the teeth of the worst of the pandemic in terms of cases, in terms of hospitalizations, and even now in terms of deaths. And that's with mortality rates significantly lower than they were six months ago, but the case level has been so explosive that the death rates are still higher than they were at the earlier peak back in the spring. And given where hospitalizations now are and given where cases are certainly going to be, those numbers are going to keep going up. So, on the one hand we're looking at maybe half a million total dead by the time we get to end of January, February, and the next couple of months are going to be really, really hard.
On the other hand, we are now also looking at people getting vaccinated, we're looking at real solutions. And those solutions come first and foremost to the people that are by far the most vulnerable. Now, usually you would be focused on how quickly can everybody get this vaccine, but I do think it's important because this disease hits so much worse a relatively small piece of the population, the very old and those with serious pre-existing conditions, and particularly when those two groups collide. And those are precisely the people along with first responders and hospitals that are going to be getting the vaccines first.
So, I mean, irrespective of difficulties in rollout, irrespective in fake news around anti-vaxxer sentiment, we're going to see within two months a very, very significant reduction in the mortality rate of this disease, because the people that are most vulnerable are suddenly going to be vaccinated. And they'll only get some immunity immediately, they'll need to get that second course, the booster shot, which gets them up to 95% and that takes a few weeks after the first shot, but still, that's a very positive outcome.
Having said that, in terms of getting the country and getting the world back up and running there is an enormous degree of uncertainty around what happens next year on how quickly we're going to be able to roll out the vaccine. I just saw from Secretary of Health and Human Services, Azar, an expectation that most people in the US are going to be able to be vaccinated by second quarter. I agree that that is possible, it is the best-case scenario, it is absolutely not something you want to do bet on right now, and there are a few reasons for it.
The first is that we have no idea how difficult it is going to be to produce and roll out this vaccine, these vaccines that we're using Pfizer and Moderna. These are the two that everyone in the US will want to take, they're the two that have the highest degree of efficiency. But they're also the two with the very difficult infrastructure requirements, the serious cold chain requirements, in the case of Pfizer, also a need to dilute the vaccine on site before it's given to patients and that requires specialized labor which is already stretched.
So you've got significant infrastructure needs. You're also talking about producing at massive scale vaccines using technologies that have never been produced before. I mean, Pfizer's produced a lot of vaccines, they've been around for a long, long time, they're a big, big pharmaceutical company, global pharmaceutical company, but no one's ever produced an mRNA vaccine before. Moderna has never produced anything before, they've been around for 10 years, this is their first commercial product. So I mean, everything has to go right to get it out there by April.
And when you hear people talking about side effects, some of those are I'm sure going to be exaggerated, some of those side effects we don't necessarily know at scale yet. I spoke with a friend of mine who's on the Coronavirus Task Force for Biden, he took both courses of the Moderna vaccine and after the booster shot, he was out for three days with a heavy fever and wasn't able to go to work. And I can imagine a lot of people thinking they take the first shot, and they say, "Ah, I didn't feel great after that first shot, I don't really need to take the second shot, nevermind." And then suddenly you don't have 95% effective effectiveness, you have 50 or 60% effectiveness and it's a radically different story in terms of getting the vaccines out there. Then there's also huge difference between if 80% of the people say they'll take it, and if only 60% do. And anti-vax sentiment in the United States is reasonably high and there's going to be massive disinformation that's going to be put out in an unprecedented polarization of social media in the United States right now.
I mean, when a majority of Republicans think the election was stolen, how many people are going to think that this vaccine is unsafe or that one of the vaccines is unsafe and then decide they want to take the other one, but it's not available for everybody. I mean, there are a lot of things that can go wrong, can go wrong around information, can go wrong around manufacturing, can go wrong around distribution.
And then you've got the global side of this, which is also really interesting. One of the things we don't know is how long your immunity lasts once you've taken both courses of these vaccines, is it six months to 12 months? Is it 18 months? We have no idea. The United States has ordered an enormous amount of these vaccines, and if we knew that the vaccines were going to last for a year or two years, there would be a significant willingness after the US produces to start exporting a lot of that vaccine to other countries. On the other hand, if you've got problems in your manufacturing, in your distribution and/or if there's real uncertainty around how long your immunity lasts, the United States and other countries are going to want to stockpile a lot more of the vaccine than they otherwise would, which means they're not going to be exporting it to other countries.
You know who will be exporting it to other countries? China. They're doing a lot of producing, their vaccine isn't as good, but it doesn't require the cold chain, just basic refrigeration. And also, they don't need a lot of vaccines for China itself, at least not near term, because they've got massive surveillance capabilities and quarantine capabilities, they can demand that of their population. They'll give it to the frontline workers, but most Chinese people don't necessarily need the vaccine if you've already hammered down the virus, right? I mean, it's like New Zealand, for example. It's like Australia today, for example. Which means China's going to be engaging and exporting all of these vaccines internationally, whether the US can or will is an uncertainty right now, that's a massive difference between those two countries and potentially leads to big, big conflict between the United States and China and the issue that is the most important next year, which is how are we doing on vaccines? It matters to getting our economies restarted, it matters to unemployment, it matters to growth, and it matters to geopolitics.
A lot of uncertainty here, we hope for the best-case scenario, it is a real scenario, it is plausible. I mean, the United States did a good job on the economics in 2020 until very recently, did a lousy job on the healthcare response to coronavirus in terms of masking and PPE and all of the rest. But so far has done a very good job, some of the world's best in terms of vaccine development. Now we have to see for 2021, how the United States is going to do on vaccine production and distribution, and as of right now, we don't know. That level of uncertainty is probably greater than any near-term issue I can imagine that we knew about it, but we just didn't know how well it was going to work, the impact that's going to have on so many factors in the US and globally is just massive, something we'll be paying an enormous attention to and rooting for quite a bit over the coming months.
So that's enough for me for now, hope you guys are well, stay safe and avoid people.
Keep reading...Show less
More from Quick Take
Quick Take
Dec 02, 2025
Europe divided as US pushes Ukraine-Russia peace deal
November 24, 2025
Trump escalates sanctions against Russia
November 10, 2025
Is Abu Dhabi becoming the global capital of AI development?
November 02, 2025
What the Trump-Xi meeting means for US-China relations
October 30, 2025
Trump’s East Wing demolition, Binance pardon, and tariffs on Canada
October 27, 2025
Trump brokers peace: Hostages freed and guns fall silent in Gaza
October 13, 2025
Trump's role in brokering Israel-Hamas deal
October 09, 2025
America’s short-term wins vs. long-term risks
October 06, 2025
Israel is facing real consequences over Gaza annexation plans
September 29, 2025
Is Israel risking global isolation over Gaza?
September 22, 2025
Charlie Kirk's assassination will make things worse in the US
September 15, 2025
Russia-Ukraine war escalation
September 08, 2025
China’s push for a new world order
September 02, 2025
Is the US preparing to strike Venezuela?
August 27, 2025
Is American capitalism still capitalism?
August 25, 2025
Zelensky, Trump, and NATO: A united front on Ukraine?
August 18, 2025
Trump and Putin to meet in Alaska to discuss Ukraine
August 11, 2025
US government rescinds West Point role for former cyber director
August 04, 2025
US-EU trade deal marks a win for Trump
July 28, 2025
The US, China, and the critical minerals question
July 21, 2025
Epstein conspiracies divide Trump's MAGA base
July 14, 2025
US-Brazil relations in crisis
July 10, 2025
Elon Musk vows to start a new political party
July 07, 2025
What Zohran Mamdani’s win really signals for US politics
June 30, 2025
Iran's retaliation shows strategic weakness
June 23, 2025
US enters war with Iran: What comes next?
June 22, 2025
Iran looks to negotiate ceasefire
June 16, 2025
Elon vs. Trump: Billionaire fallout goes public
June 06, 2025
Elon Musk steps down from Trump administration
May 29, 2025
Trump's weekend of geopolitical success
May 12, 2025
Can Trump and Carney reset US-Canada relations?
May 07, 2025
Trump’s ‘less is more’ message is un-American
May 05, 2025
Ian Bremmer on Trump's first 100 days
April 28, 2025
Trump’s America: A kleptocracy but not a police state
April 23, 2025
Inside the Harvard-Trump showdown
April 21, 2025
Can the US win by undoing globalization?
April 14, 2025
Who benefits from Trump's tariff wall?
April 07, 2025
Trump's tariffs & the end of globalization
April 03, 2025
Leaked Signal chat shows Trump team's mindset
March 26, 2025
What Trump team's war plans leak revealed
March 25, 2025
Is Europe in trouble as the US pulls away?
March 24, 2025
Putin-Trump Ukraine call is a small win for both sides
March 18, 2025
What will Trump offer Putin in Ukraine ceasefire talks?
March 17, 2025
Ukraine ceasefire deal now awaits Putin's response
March 11, 2025
Can Europe broker a Ukraine ceasefire?
March 03, 2025
What Trump-Zelensky fallout means for Ukraine war
March 01, 2025
Why the US-Ukraine minerals deal changed
February 26, 2025
Germany's close election limits its ability to lead Europe
February 24, 2025
Ukraine hopes for Europe's help as US negotiates with Russia
February 18, 2025
JD Vance stuns Munich conference with critique on European democracy
February 14, 2025
Trump-Putin chat over Ukraine "deeply" worries Europe
February 13, 2025
What is Trump's Gaza playbook?
February 10, 2025
Why cutting USAID will hurt American foreign policy
February 05, 2025
Why is Trump starting a trade war with Canada?
February 02, 2025
How Trump's assertive foreign policy impacts international relations
January 27, 2025
Trump's Davos address sets up big shifts in US strategy
January 24, 2025
From Davos: How global leaders are grappling with Trump’s return
January 20, 2025
Ian Bremmer on the forces behind the geopolitical recession
January 17, 2025
What Greenlanders might want from a deal with Trump
January 13, 2025
New Year's Day terror attacks highlight America's divisions
January 03, 2025
MAGA, the American Dream and immigration
December 27, 2024
What Trump's Panama Canal threats reveal about today's geopolitics
December 23, 2024
A look back at the Top Risks of 2024
December 22, 2024
What's next for South Korea after President Yoon's impeachment?
December 16, 2024
Ian Bremmer on Assad's fall
December 08, 2024
Why South Korea's president declared martial law
December 03, 2024
Syrian rebel forces take Aleppo
December 01, 2024
Putin's strategy in Ukraine ahead of Trump's return
November 25, 2024
Global leaders scramble to align with Trump
November 18, 2024
Trump's plans for policy & personnel
November 12, 2024
Ian Bremmer on Trump’s win
November 06, 2024
Ian Bremmer on the 2024 US election ahead
November 04, 2024
After Israel's response to Iran, what's next?
October 28, 2024
A global leadership void and ongoing wars
October 21, 2024
Israel's next move
October 14, 2024
How October 7th changed Israel and the Middle East
October 07, 2024
Israel strikes: Why Hezbollah remains silent
September 30, 2024
Israel vs. Hezbollah
September 24, 2024
Ian Bremmer on Trump second assassination attempt
September 16, 2024
Harris wins debate
September 11, 2024
Brazil's X ban becomes a rallying cry for Bolsonaro
September 09, 2024
Israelis push Netanyahu for cease-fire after Hamas kills hostages
September 03, 2024
Israel & Hezbollah: What to expect next
August 26, 2024
GZERO Series
GZERO Daily: our free newsletter about global politics
Keep up with what’s going on around the world - and why it matters.


































































































